期刊
BRITISH JOURNAL OF CANCER
卷 109, 期 2, 页码 342-350出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.334
关键词
sorafenib; tetrandrine; synergistic antitumour; apoptosis
类别
资金
- National Basic Research Program of China [2010CB529800]
- National Nature Science Foundation of China [81072151, 81273540]
- Distinguished Youth Foundation of Hubei Province of China [2012FFA019]
- Chinese 111 project [B06018]
- Major Scientific and Technological Special Project for the 'Significant Creation of New Drugs' [2011ZX09102-001-32, 2010ZX09401]
Background: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine kinases that has been approved for the clinical treatment of advanced renal and liver cancer. Combining sorafenib with other agents has been shown to improve its antitumour efficacy by not only reducing the toxic side effects but also preventing primary and acquired resistance to sorafenib. We have previously observed that tetrandrine exhibits potent antitumour effects in human hepatocellular carcinoma. In this study, we investigated the synergistic antitumour activity of sorafenib in combination with tetrandrine. Methods: This was a two-part investigation that included the in vitro effects of sorafenib in combination with tetrandrine on cancer cells and the in vivo antitumour efficacy of this drug combination on tumour xenografts in nude mice. Results: Combined treatment showed a good synergistic antitumour effect yet spared nontumourigenic cells. The potential molecular mechanism may be mainly that it activated mitochondrial death pathway and induced caspase-dependent apoptosis in the cancer cells. Accumulation of intracellular reactive oxygen species (ROS) and subsequent activation of Akt may also be involved in apoptosis induction. Conclusion: The antitumour activity of sorafenib plus tetrandrine may be attributed to the induction of the intrinsic apoptosis pathway through ROS/Akt signaling. This finding provides a novel approach that may broaden the clinical application of sorafenib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据